PURPOSE:The effect of statins on prostate cancer recurrence has been investigated in several studies with inconsistent results.
We investigated whether statins were associated with biochemical recurrence in a large cohort of men after radical prostatectomy. We also performed a meta-analysis of existing studies.
MATERIALS AND METHODS:A total of 1,446 patients who underwent radical prostatectomy at New York University were followed a median of 57 months for biochemical recurrence events. Baseline demographic and clinical characteristics were compared between 437 statin users and 1,009 nonusers. Kaplan-Meier curves and Cox models were used to examine biochemical recurrence-free survival by statin use. A meta-analysis was performed with data from our cohort and 5 published studies using the random effects model.
xxxStatin users were slightly older and more likely to have diabetes (p < 0.01). They were similar to nonusers in race and body mass index. Although preoperative prostate specific antigen and tumor stage were similar between the 2 groups, the proportion of patients with pathological Gleason score 7-10 tumors was slightly higher among statin users (p = 0.03). The biochemical recurrence-free survival rate was 87.4% and 89.0% for statin users and nonusers, respectively, at the end of followup (log rank p = 0.26). Overall biochemical recurrence was not associated with statin use (HR 1.15, 95% CI 0.82-1.61). Results were similar when patients were stratified by D'Amico low and intermediate or high risk groups. Meta-analysis revealed no overall association between statins and biochemical recurrence (pooled HR 1.00, 95% CI 0.80-1.19).
CONCLUSIONS: Our findings are consistent with the results of the meta-analysis, which indicated that preoperative statin use does not impact the overall risk of biochemical recurrence.
Written by:
Mass AY, Agalliu I, Laze J, Lepor H. Are you the author?
Department of Urology, New York University School of Medicine, New York and Department of Epidemiology and Population Health, Albert Einstein College of Medicine (IA), Bronx, New York.
Reference: J Urol. 2012 Sep;188(3):786-91.
doi: 10.1016/j.juro.2012.05.011
PubMed Abstract
PMID: 22818136
UroToday.com Prostate Cancer Section
